Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
JA Fraietta, RD Schwab, MV Maus - Seminars in oncology, 2016 - Elsevier
Adoptive cell immunotherapy for the treatment of chronic lymphocytic leukemia (CLL) has
heralded a new era of synthetic biology. The infusion of genetically engineered, autologous
chimeric antigen receptor (CAR) T cells directed against CD19 expressed by normal and
malignant B cells represents a novel approach to cancer therapy. The results of recent
clinical trials of CAR T cells in relapsed and refractory CLL have demonstrated long-term
disease-free remissions, underscoring the power of harnessing and redirecting the immune …
heralded a new era of synthetic biology. The infusion of genetically engineered, autologous
chimeric antigen receptor (CAR) T cells directed against CD19 expressed by normal and
malignant B cells represents a novel approach to cancer therapy. The results of recent
clinical trials of CAR T cells in relapsed and refractory CLL have demonstrated long-term
disease-free remissions, underscoring the power of harnessing and redirecting the immune …